Grifols (GRFS) Stock Price, News & Analysis

Company Overview

Grifols S.A. is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases.

Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases. Grifols collects plasma through a network of donation centers and operates manufacturing and research facilities in multiple countries.

Grifols also provides diagnostic solutions for transfusion medicine, including blood-typing, screening and laboratory systems, instruments and reagents. Its products and services are supplied to hospitals, clinical laboratories, blood banks and healthcare providers across North America, Europe and other international markets.

Key Stats

• Today's Range: $7.39 to $7.45
• 50-Day Range: $7.21 to $8.25
• 52-Week Range: $6.96 to $10.23
• Volume: 600,099 shs
• Average Volume: 384,646 shs
• Market Capitalization: $5.06 billion
• P/E Ratio: 39.16
• Dividend Yield: 1.21%
• Price Target: $10.00
• Consensus Rating: Reduce

Grifols Stock Analysis - MarketRank™

Grifols scored higher than 95% of companies evaluated by MarketBeat, and ranked 15th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Grifols has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Grifols has a consensus price target of $10.00, representing about 34.4% upside from its current price of $7.44.

Amount of Analyst Coverage

Grifols has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 5.0 / 5
• Proj. Earnings Growth: 24.07%

Earnings Growth

Earnings for Grifols are expected to grow by 24.07% in the coming year, from $1.08 to $1.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Grifols is 39.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of Grifols is 39.16, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.29.

Price to Earnings Growth Ratio

Grifols has a PEG Ratio of 0.27. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Grifols has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.50% of the float of Grifols has been sold short.

Short Interest Ratio / Days to Cover

Grifols has a short interest ratio ("days to cover") of 8.36.

Change versus previous month

Short interest in Grifols has recently decreased by 2.82%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Grifols pays a meaningful dividend of 1.16%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Grifols does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Grifols is 47.37%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Grifols will have a dividend payout ratio of 6.72% next year. This indicates that Grifols will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.60

News Sentiment

Grifols has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Grifols this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Grifols insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.19% of the stock of Grifols is held by insiders.

Percentage Held by Institutions

Grifols has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/04/2021
• Record date for 7/9 Dividend: 7/02/2026
• Ex-Dividend for 7/9 Dividend: 7/02/2026
• Dividend Payable: 7/09/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GRFS
• CIK: 1438569
• Web: www.grifols.com
• Phone: (493) 571-0221
• Fax: 34-93-571-0267
• Employees: 25,247
• Year Founded: 1909

Price Target and Rating

• Average Price Target for Grifols: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +34.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.19
• Trailing P/E Ratio: 39.16
• Forward P/E Ratio: 6.89
• P/E Growth: 0.27
• Net Income: $454.82 million
• Net Margins: 5.54%
• Pretax Margin: 8.18%
• Return on Equity: 6.21%
• Return on Assets: 2.39%

Debt

• Debt-to-Equity Ratio: 1.10
• Current Ratio: 2.37
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: $8.51 billion
• Price / Sales: 0.59
• Cash Flow: $1.43 per share
• Price / Cash Flow: 5.20
• Book Value: $12.64 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 680,580,000
• Free Float: 679,282,000
• Market Cap: $5.06 billion
• Optionable: Optionable
• Beta: 0.67